Effects of ARV-110 in the liver proteome in DHT-treated mice.

Supplementary Data for:Androgen Receptor PROTAC ARV-110 Ameliorates Metabolic Complications in a Mouse Model of Polycystic Ovary SyndromeJelina Basnet1,3,4,5, Samar Rezq1,3,4,5, Alexandra M. Huffman1,3,4,5, Tolulope E. Asala1,3, Licy L. Yanes Cardozo1,2,3,4,5,6, Damian G. Romero1,3,4,5Departments of 1Pharmacology and Toxicology, and 2Medicine (Endocrinology), 3Mississippi Center of Excellence in Perinatal Research, 4Women’s Health Research Center, 5Cardiovascular-Renal Research Center, University of Mississippi Medical Center, Jackson, Mississippi, USAEffects of ARV-110 in the liver proteome in DHT-treated mice. Mice were treated with dihydrotestosterone (DHT) or control (CON) for 12 weeks. During the last 8 weeks, mice were additionally treated with low-dose ARV-110 (ARV-L, 1 mg/kg/day), high-dose ARV-110 (ARV-H, 10 mg/kg/day), or vehicle (VEH).